Tocilizumab for COVID-19 Acute Respiratory Distress Syndrome: Outcomes Assessment Using the WHO Ordinal Scale

Introduction Cytokine release syndrome in COVID-19 is characterized by hyperinflammation, which manifests as acute respiratory distress syndrome (ARDS), multiorgan failure, and high inflammatory parameters. Tocilizumab, an interleukin 6 (IL-6) antagonist has been used in COVID-19 ARDS with conflicti...

Descripción completa

Detalles Bibliográficos
Autores principales: Nasir, Nosheen, Mahmood, Faisal, Habib, Kiren, Khanum, Iffat, Jamil, Bushra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2020
Materias:
Internal Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7829612/
https://www.ncbi.nlm.nih.gov/pubmed/33510989
http://dx.doi.org/10.7759/cureus.12290

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7829612/
https://www.ncbi.nlm.nih.gov/pubmed/33510989
http://dx.doi.org/10.7759/cureus.12290

Ejemplares similares